Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.730,49
0,01%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Sutro Biopharma Inc (STRO) Sutro Biopharma Inc (STRO) Notizie

STRO

Sutro Biopharma (STRO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:STRO
DataOraFonteTitoloSimboloCompagnia
17/05/202423:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:STROSutro Biopharma Inc
13/05/202422:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STROSutro Biopharma Inc
13/05/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
13/05/202422:30GlobeNewswire Inc.Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
30/04/202414:00GlobeNewswire Inc.Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 TrialNASDAQ:STROSutro Biopharma Inc
02/04/202412:18GlobeNewswire Inc.Sutro Biopharma Announces Pricing of $75 Million Underwritten OfferingNASDAQ:STROSutro Biopharma Inc
25/03/202421:30GlobeNewswire Inc.Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
07/03/202422:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
27/02/202422:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:STROSutro Biopharma Inc
13/02/202418:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:STROSutro Biopharma Inc
09/02/202422:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:STROSutro Biopharma Inc
06/02/202422:05GlobeNewswire Inc.Sutro Biopharma to Participate in Upcoming Investor ConferencesNASDAQ:STROSutro Biopharma Inc
29/01/202423:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STROSutro Biopharma Inc
04/01/202422:05GlobeNewswire Inc.Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADCNASDAQ:STROSutro Biopharma Inc
14/12/202322:05GlobeNewswire Inc.Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024NASDAQ:STROSutro Biopharma Inc
11/12/202322:05GlobeNewswire Inc.Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023NASDAQ:STROSutro Biopharma Inc
04/12/202322:05GlobeNewswire Inc.Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:STROSutro Biopharma Inc
27/11/202322:00GlobeNewswire Inc.Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine CandidatesNASDAQ:STROSutro Biopharma Inc
22/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:STROSutro Biopharma Inc
21/11/202322:05GlobeNewswire Inc.Sutro Biopharma Promotes Jane Chung to President and Chief Operating OfficerNASDAQ:STROSutro Biopharma Inc
13/11/202323:18Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:STROSutro Biopharma Inc
13/11/202322:30GlobeNewswire Inc.Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
22/10/202310:25GlobeNewswire Inc.Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023NASDAQ:STROSutro Biopharma Inc
16/10/202322:05GlobeNewswire Inc.Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC ConferenceNASDAQ:STROSutro Biopharma Inc
19/09/202322:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
19/09/202314:00GlobeNewswire Inc.Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific OfficerNASDAQ:STROSutro Biopharma Inc
10/08/202322:30GlobeNewswire Inc.Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
30/06/202300:29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:STROSutro Biopharma Inc
26/06/202314:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:STROSutro Biopharma Inc
26/06/202314:00GlobeNewswire Inc.Sutro Biopharma and Blackstone Announce Royalty Financing CollaborationNASDAQ:STROSutro Biopharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:STRO

La tua Cronologia

ASE
VARDA
BIT
F09568
Vontobel Financial Produ...
USOTC
HRBR
Harbor Diversified (PK)
DBI
4J0C
I.DE.MS.EUR.CL.CH.ESG EO
NASDAQ
NTRNP
Northern Trust Corp.
EU
CAHAX
Credit Agricole home Loa...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network